PLoS ONE (Jan 2014)

Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions.

  • Yoshikazu Kishino,
  • Tomohisa Seki,
  • Jun Fujita,
  • Shinsuke Yuasa,
  • Shugo Tohyama,
  • Akira Kunitomi,
  • Ryota Tabei,
  • Kazuaki Nakajima,
  • Marina Okada,
  • Akinori Hirano,
  • Hideaki Kanazawa,
  • Keiichi Fukuda

DOI
https://doi.org/10.1371/journal.pone.0097397
Journal volume & issue
Vol. 9, no. 5
p. e97397

Abstract

Read online

Recently, induced pluripotent stem cells (iPSCs) were established as promising cell sources for revolutionary regenerative therapies. The initial culture system used for iPSC generation needed fetal calf serum in the culture medium and mouse embryonic fibroblast as a feeder layer, both of which could possibly transfer unknown exogenous antigens and pathogens into the iPSC population. Therefore, the development of culture systems designed to minimize such potential risks has become increasingly vital for future applications of iPSCs for clinical use. On another front, although donor cell types for generating iPSCs are wide-ranging, T cells have attracted attention as unique cell sources for iPSCs generation because T cell-derived iPSCs (TiPSCs) have a unique monoclonal T cell receptor genomic rearrangement that enables their differentiation into antigen-specific T cells, which can be applied to novel immunotherapies. In the present study, we generated transgene-free human TiPSCs using a combination of activated human T cells and Sendai virus under defined culture conditions. These TiPSCs expressed pluripotent markers by quantitative PCR and immunostaining, had a normal karyotype, and were capable of differentiating into cells from all three germ layers. This method of TiPSCs generation is more suitable for the therapeutic application of iPSC technology because it lowers the risks associated with the presence of undefined, animal-derived feeder cells and serum. Therefore this work will lead to establishment of safer iPSCs and extended clinical application.